Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Near-term catalysts skew positive, led by the imminent Q3 2026 earnings report (Nov 3) with a favorable Zacks ESP setup and the newly launched Japan IMCIVREE commercialization; analyst price target hikes reinforce constructive sentiment.
Rhythm will report Q3 2026 financial results and provide a corporate update on Nov 3, 2026. Consensus expects a loss of $0.68 per share on revenue of $84.47M (up ~64.7% YoY); Zacks flags an Earnings ESP of +1.38% and a history of beats, raising the odds of an EPS surprise that could move the stock.
Rhythm Pharmaceuticals Press ReleaseRhythm launched IMCIVREE (setmelanotide) in Japan for acquired hypothalamic obesity following MHLW approval and inclusion on the National Health Insurance price list, the first approved therapy for this indication in Japan. The launch opens a new revenue stream (est. 5,000-8,000 patients), though initial uptake may be gradual due to fortnightly prescription renewal requirements.
StockTitan / Rhythm Press ReleaseH.C. Wainwright lifted its RYTM price target to $130 from $105 while keeping a Buy rating, citing the Japan approval and launch outlook. The higher target versus the ~$90.78 trading level implies meaningful upside and reinforces the strong-buy analyst consensus ($105-$160 range), supporting near-term sentiment.
Investing.comCEO David Meeker will present at the Guggenheim Healthcare Innovation Conference on Nov 9 and CFO Hunter Smith at the Stifel Healthcare Conference on Nov 11. These appearances offer near-term opportunities for management to frame the Japan launch and pipeline narrative to investors, a potential sentiment driver.
Rhythm Pharmaceuticals Press Release